Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

Dong-shan Zhu; Jing-yao Dong; Yao-yao Xu; Xin-tong Zhang; Shi-bo Fu; Wei Liu

doi:10.12659/MSM.927106

17 August 2020 : Animal Research

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

Dong-shan Zhu^1ABCDEF, Jing-yao Dong^1BCF, Yao-yao Xu^2BCD, Xin-tong Zhang^2BCD, Shi-bo Fu^2ACEFG, Wei Liu^1ACEFG*

DOI: 10.12659/MSM.927106

Med Sci Monit 2020; 26:e927106

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Omipalisib was identified as a potential agent against Esophageal squamous cell carcinoma (ESCC). (A) MTT assay was used to screen compounds in a 1404-compound library. (B) In total, 13 compounds showed inhibitory effects on 4 ESCC cell lines. (C) Chemical structure of omipalisib.

Back to the Article

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

Your Privacy